Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9233140-B2
Publication Date
2016-01-12
Expiration Date
Abstract
The current standard of care for the treatment of allergic airway diseases include short and long acting beta-agonists, and inhaled or systemic corticosteroids, cromolyn and xanthines that all have the potential of detrimental side-effects. The present invention describes a new mechanistic protein-based therapeutic approach for the treatment of allergic airway disease and diseases associated with excessive Th2 pathology. The present invention relates to the surprising discovery that serum amyloid P (SAP) demonstrates a therapeutic affect in the treatment of hypersensitive disorders.
Core Innovation
The invention provides a mechanistic, protein-based therapy for treating hypersensitivity disorders by administering serum amyloid P (SAP) or SAP agonists. It focuses on treating allergic airway diseases driven by excessive Th2 pathology, including allergic rhinitis, allergic sinusitis, allergic-asthma, allergic bronchoconstriction, allergic dyspnea, allergic increase in mucus production in lungs, and pneumonitis. The therapy is directed to immune mechanisms involving CD4+ T cells and Th2-associated cytokine programs.
The disclosed approach uses SAP protein modalities, including a SAP polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1, and SAP agonist modalities. SAP agonists are described as including anti-FcγR antibodies, aggregated/cross-linked IgG, peptidomimetics, FcγR crosslinkers, aptamers, and others. Immune rationale includes modulation of IgE and mast cells, cytokines including IL-4, IL-5, IL-10, IL-13, IFN-γ, and signaling factors such as STAT-6 and GATA-3.
The invention includes induction of regulatory T cells and associated responses, including IL-10 and FoxP3-associated regulatory responses. In the described preclinical fungal asthma mouse model, SAP treatment reduces airway hyperresponsiveness and increases IL-10/FoxP3-associated regulatory responses. The target outcomes described include delaying onset and reducing severity and/or days afflicted in allergic airway disease contexts.
Claims Coverage
The independent claim covers treatment of allergic airway disease by administering a therapeutically effective amount of an SAP protein comprising SEQ ID NO:1. One independent-claim feature is the SAP protein sequence limitation, and another is the specified allergic airway disease scope.
Treating allergic airway disease with SEQ ID NO:1 SAP protein
A method for treating an allergic airway disease in a patient by administering to a patient in need thereof a therapeutically effective amount of a serum amyloid P (SAP) protein, wherein the SAP protein comprises a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1.
Allergic airway disease scope including rhinitis, sinusitis, asthma, and pneumonitis
The method where the allergic airway disease is allergic rhinitis, allergic sinusitis, allergic-asthma, allergic bronchoconstriction, allergic dyspnea, allergic increase in mucus production in lungs, or pneumonitis.
The claimed invention centers on administering a therapeutically effective amount of an SAP protein containing the polypeptide amino acid sequence of SEQ ID NO:1 to treat specified allergic airway diseases.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?